CoTherix, Inc. To Webcast Presentations At Two Upcoming Investor Conferences
BRISBANE, Calif., Oct. 27 /PRNewswire-FirstCall/ -- CoTherix, Inc. announced today that Donald J. Santel, Chief Executive Officer, will provide a company overview at two upcoming investor conferences. A live transmission of the presentations will be available through the CoTherix website at www.cotherix.com. The following is the schedule of presentations:
* Monday, November 6, 2006, 10:35a.m. ET, Rodman & Renshaw 8th Annual Healthcare Conference * Wednesday, November 8, 2006, 9:45a.m. ET, CIBC World Markets 17th Annual Healthcare Conference About CoTherix, Inc.
CoTherix, Inc. is a biopharmaceutical company focused on licensing, developing and commercializing therapeutic products for the treatment of cardiovascular disease. CoTherix currently markets Ventavis(r) (iloprost) Inhalation Solution in the United States for the treatment of PAH (WHO Group I). The Company is also developing fasudil, a rho-kinase inhibitor, for the treatment of PAH and stable angina. CoTherix and the CoTherix logo are trademarks of CoTherix, Inc. Ventavis is a registered trademark of Schering AG. More information can be found at www.cotherix.com or www.4ventavis.com.
CoTherix, Inc.CONTACT: Anne Bowdidge, Senior Director of Investor Relations of CoTherix,Inc., +1-650-808-6551
Web site: http://www.cotherix.com//